Literature DB >> 22605909

Multiple sclerosis review.

Marvin M Goldenberg.   

Abstract

Entities:  

Year:  2012        PMID： 22605909      PMCID： PMC3351877     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  47 in total

1.  Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.

Authors:  Monica A Rojas; Noel G Carlson; Thomas L Miller; John W Rose
Journal:  Ther Adv Neurol Disord       Date:  2009-09       Impact factor: 6.570

2.  European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

Authors:  G Comi; M Filippi; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

3.  Insight into the mechanism of laquinimod action.

Authors:  W Brück; C Wegner
Journal:  J Neurol Sci       Date:  2011-03-22       Impact factor: 3.181

4.  Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alex Tselis
Journal:  Curr Opin Investig Drugs       Date:  2010-05

5.  Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.

Authors:  Francesco Patti; Ester Reggio; Filippo Palermo; Teresa Fiorilla; Guido Politi; Alessandra Nicoletti; Arturo Reggio
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

Review 6.  Diagnosis and management of multiple sclerosis.

Authors:  Peter A Calabresi
Journal:  Am Fam Physician       Date:  2004-11-15       Impact factor: 3.292

7.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

8.  Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

Authors:  Hans-Peter Hartung; Richard Gonsette; Nikolaus König; Hubert Kwiecinski; Andreas Guseo; Sean P Morrissey; Hilmar Krapf; Thomas Zwingers
Journal:  Lancet       Date:  2002 Dec 21-28       Impact factor: 79.321

9.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422
View more
  160 in total

Review 1.  Immunoregulatory Effects of Tolerogenic Probiotics in Multiple Sclerosis.

Authors:  Hadi Atabati; Esmaeil Yazdanpanah; Hamed Mortazavi; Saeed Gharibian Bajestani; Amir Raoofi; Seyed-Alireza Esmaeili; Azad Khaledi; Ehsan Saburi; Jalil Tavakol Afshari; Thozhukat Sathyapalan; Abbas Shapouri Moghaddam; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity.

Authors:  Erez Eitan; Emmette R Hutchison; Nigel H Greig; David Tweedie; Hasan Celik; Soumita Ghosh; Kenneth W Fishbein; Richard G Spencer; Carl Y Sasaki; Paritosh Ghosh; Soumen Das; Susheela Chigurapati; James Raymick; Sumit Sarkar; Srinivasulu Chigurupati; Sudipta Seal; Mark P Mattson
Journal:  Exp Neurol       Date:  2015-08-13       Impact factor: 5.330

Review 3.  Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis.

Authors:  Sheridan M Hoy
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

4.  Reproducibility measurement of glutathione, GABA, and glutamate: Towards in vivo neurochemical profiling of multiple sclerosis with MR spectroscopy at 7T.

Authors:  Hetty Prinsen; Robin A de Graaf; Graeme F Mason; Daniel Pelletier; Christoph Juchem
Journal:  J Magn Reson Imaging       Date:  2016-06-28       Impact factor: 4.813

5.  Relationships between accelerometer-measured and multiple sclerosis: a 2-sample Mendelian randomization study.

Authors:  Hui Lu; Peng-Fei Wu; Rui-Zhuo Li; Wan Zhang; Guo-Xiang Huang
Journal:  Neurol Sci       Date:  2021-01-07       Impact factor: 3.307

6.  Access to Care for Multiple Sclerosis in Times of Economic Crisis in Greece--the HOPE II Study.

Authors:  Kyriakos Souliotis; Elena Alexopoulou; Manto Papageorgiou; Anastasia Politi; Panagiota Litsa; Xenophon Contiades
Journal:  Int J Health Policy Manag       Date:  2015-09-27

7.  Age of the donor reduces the ability of human adipose-derived stem cells to alleviate symptoms in the experimental autoimmune encephalomyelitis mouse model.

Authors:  Brittni A Scruggs; Julie A Semon; Xiujuan Zhang; Shijia Zhang; Annie C Bowles; Amitabh C Pandey; Kathleen M P Imhof; Allan V Kalueff; Jeffrey M Gimble; Bruce A Bunnell
Journal:  Stem Cells Transl Med       Date:  2013-09-09       Impact factor: 6.940

8.  Dimethyl fumarate.

Authors:  Dennis J Cada; Terri L Levien; Danial E Baker
Journal:  Hosp Pharm       Date:  2013-09

9.  Association of IL-13 single nucleotide polymorphisms in Iranian patients to multiple sclerosis.

Authors:  Narges Seyfizadeh; Tohid Kazemi; Mehdi Farhoudi; Mohammad Reza Aliparasti; Homayoun Sadeghi-Bazargani; Shohreh Almasi; Zohreh Babaloo
Journal:  Am J Clin Exp Immunol       Date:  2014-12-05

10.  Motor reaction time and accuracy in patients with multiple sclerosis: effects of an active computerized training program.

Authors:  Amir Dana; Saleh Rafiee; Amin Gholami
Journal:  Neurol Sci       Date:  2019-05-04       Impact factor: 3.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.